New Prevention Study Coming
teplizumab prevent or delay type 1 diabetes?
TrialNet study will test whether treatment with a drug called
teplizumab, also known as anti-CD3 mAb, can prevent or delay type 1
diabetes in high-risk (autoantibody positive) relatives of people
with type 1 diabetes.
Study for Newly Diagnosed Patients Taking Place at
are the benefits of early intensive glucose
A new TrialNet study is testing whether
early intensive glucose control—beginning within 7 days of diagnosis
and continuing through the first 2 years—will help people retain
their own insulin production for a longer period.
STUDY FINDINGS AND
helps preserve insulin production in people newly
A recent TrialNet study proves that
rituximab, a drug used to treat some types of cancer, also helps
protect insulin-producing beta cells in people newly diagnosed with
type 1 diabetes.
study finds MMF/DZB therapy ineffective in saving beta cell
A multi-center study, led by TrialNet
researchers at 13 sites in North America and Europe, found that the
drugs mycophenolate mofetil (MMF) and daclizumab (DZB) failed to
halt loss of insulin-producing beta cells in patients newly
diagnosed with type 1 diabetes.
New Onset study meets enrollment goal in record
The GAD New Onset Study recently met its
enrollment goal of 126 patients. The goal was met in 13 months,
exceeding expectations and demonstrating great interest in research
by those newly diagnosed with type 1 diabetes. The GAD New Onset
Study is exploring whether repeated injections of a protein called
glutamic acid decarboxylase (GAD) will help newly diagnosed patients
(diagnosed within 90 days) continue producing insulin. TrialNet is
currently planning additional new onset studies that will be
launched later this year.
TrialNet Studies Currently Enrolling
History Study of the Development of Type 1 Diabetes: Screening
and observing relatives of people with type 1 diabetes to learn more
about how the disease occurs.
Insulin for Prevention of Type 1 Diabetes Study: Testing whether
a daily oral insulin capsule can prevent or delay type 1 diabetes in
at-risk relatives of people with the disease.
Control in New Onset Diabetes: Studying whether early intensive
glucose control can help preserve insulin production.
Family of 241
inspires others to get screened for type 1 diabetes
A large extended family in New Hampshire is an inspiring example
of how families of any size can take positive steps to fight type 1
diabetes. With 241 family members living in the United States, plus
four babies on the way, the Ojalas are hosting their own type 1
diabetes family screening events with impressive results.
the Principal Investigator: Tihamer Orban, M.D.
1 Diabetes TrialNet is proud to work with the world's leading
experts in type 1 diabetes. In this issue, we feature TrialNet
principal investigator Tihamer Orban, M.D., associate investigator
at Joslin Diabetes Clinic and an instructor at Harvard Medical
DID YOU KNOW?
JDRF offers online service
to connect patients with clinical trials
Diabetes Research Foundation International (JDRF) recently
introduced the Type 1 Diabetes Clinical Trials Connection, a
resource to help people with type 1 diabetes find clinical trials of
interest to them or family members. To learn more, visit https://trials.jdrf.org/patient/
offers screening test kits by mail
If type 1
diabetes is in your family, you can order a test kit from a TrialNet
Clinical Center and take it to a local doctor’s office or lab to
collect a small blood sample. The kit is then sent back to the
Clinical Center for processing and analysis by TrialNet's lab. To
find out more, contact one of the TrialNet Clinical Centers listed